Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
- 20 March 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (9), 1527-1533
- https://doi.org/10.1200/jco.2009.25.4847
Abstract
Purpose To determine the safety, pharmacokinetics (PK), and maximum-tolerated dose (MTD) up to a prespecified target dose of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients with previously untreated, nonsquamous, stage IIIb (with pleural effusion)/IV or recurrent non–small-cell lung cancer (NSCLC). Patients and Methods In this phase 1b study, patients (n = 24) received PCB on day 1 of each 21-day cycle then dulanermin at 4 or 8 mg/kg/d for 5 consecutive days or 15 or 20 mg/kg/d for 2 consecutive days per assigned treatment cohort. Incidence of dose-limiting toxicities (DLTs), adverse events, and antidulanermin antibodies were assessed. PK parameters were recorded for each agent. Tumor response was measured by modified Response Evaluation Criteria in Solid Tumors. Results Twenty-four patients received at least one dose of dulanermin plus PCB, six in each treatment cohort. There were no DLTs. An MTD was not reached, and the drug combination was well tolerated. Treatment-emergent adverse events were generally as expected for the PCB regimen. Adverse events attributed to dulanermin were grade 1/2; no significant hepatotoxicity occurred. There was minimal impact of PCB on the PK of dulanermin. There was one confirmed complete response and 13 confirmed partial responses. The overall response rate was 58% (95% CI, 37 to 78). Median progression-free survival was 7.2 months (95% CI, 4.7 to 10.3). Conclusion Dulanermin plus PCB was well tolerated with no occurrence of DLTs and demonstrated antitumor activity in this patient population. Dulanermin at 8 mg/kg/d for 5 days and 20 mg/kg/d for 2 days every 3 weeks in combination with PCB is being studied in a phase II trial.Keywords
This publication has 23 references indexed in Scilit:
- Directing cancer cells to self-destruct with pro-apoptotic receptor agonistsNature Reviews Drug Discovery, 2008
- Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)Journal of Clinical Oncology, 2008
- To kill a tumor cell: the potential of proapoptotic receptor agonistsJCI Insight, 2008
- Targeting the extrinsic apoptosis pathway in cancerCytokine & Growth Factor Reviews, 2008
- The Apoptosome: Emerging Insights and New Potential Targets for Drug DesignPharmaceutical Research, 2007
- Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Activating AgentsJournal of Clinical Oncology, 2005
- Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versionsNature Medicine, 2001
- Avoiding premature apoptosis of normal epidermal cellsNature Medicine, 2001
- TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cellsLeukemia, 1999
- Safety and antitumor activity of recombinant soluble Apo2 ligandJCI Insight, 1999